COYA
Coya Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.76
+4.62%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.0M | 7.9M | 3.6M | 6.0M | — |
| Cost of Revenue | 6.8K | 27.4K | 11.9M | 5.5M | 4.4M |
| Gross Profit | 8.0M | 7.9M | (8.3M) | 500.7K | (4.4M) |
| Operating Expenses | |||||
| R&D Expense | 18.8M | 16.7M | 11.9M | 6.0M | 4.9M |
| SG&A Expense | 11.9M | 11.4M | 8.9M | 7.8M | 4.8M |
| General & Admin Expense | 11.9M | 11.4M | 8.9M | 7.8M | 4.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 14.1K | — | (11.8M) | (5.5M) | (4.4M) |
| Total Operating Expenses | 30.6M | 28.2M | 8.9M | 8.4M | 5.4M |
| Cost and Expenses | 30.7M | 28.2M | 20.8M | 13.9M | 9.8M |
| Operating Income (EBIT) | (22.6M) | (20.3M) | (17.2M) | (7.9M) | (9.8M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | 968.5K | (957.4K) | 1.6M | 639.4K | (2.4M) |
| Non-Operating Income (excl Interest) | (545.2K) | 957.4K | (25.0K) | (543.2K) | (525.0K) |
| EBT (Pre-Tax Income) | (21.7M) | (21.2M) | (15.6M) | (7.3M) | (12.2M) |
| Income Tax Expense | 3.1K | 3.1K | (720.3K) | 723.9K | — |
| Bottom Line | |||||
| Net Income | (21.7M) | (21.2M) | (14.9M) | (8.0M) | (12.2M) |
| Earnings from Cont. Ops | (21.7M) | (21.2M) | (14.9M) | (8.0M) | (12.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (21.7M) | (21.2M) | (14.9M) | (8.0M) | (12.2M) |
| Per Share | |||||
| Basic EPS | ($1.07) | ($1.27) | ($0.98) | ($0.79) | ($1.23) |
| Diluted EPS | ($1.07) | ($1.27) | ($0.98) | ($0.79) | ($1.23) |
| Revenue Per Share | $0.34 | $0.47 | $0.23 | $0.59 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 23.5M | 16.7M | 15.2M | 10.2M | 9.9M |
| Diluted Shares Outstanding | 23.5M | 16.7M | 15.2M | 10.2M | 9.9M |
| Profitability Metrics | |||||
| EBITDA | (22.1M) | (21.2M) | (17.2M) | (7.3M) | (9.3M) |
| D&A | 19.3K | 27.4K | 27.4K | 27.4K | 27.4K |
| EBIT | (22.1M) | (21.2M) | (17.2M) | (7.4M) | (9.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026